| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| b' Esther Papaseit, Clara P\\xc3\\xa9rez-Ma\\xc3\\xb1\\xc3\\xa1, Ana Pilar P\\xc3\\xa9rez-Acevedo, Olga Hladun, M Carmen Torres-Moreno, Robert Muga, Marta Torrens, Mag\\xc3\\xad Farr\\xc3\\xa. Cannabinoids: from pot to lab. International journal of medical sciences. vol 15. issue 12. 2019-01-14. PMID:30275754.' |
in this paper we review some of the novel aspects of cannabis and cannabinoids in relation to their legal situation, changes in their composition and forms of cannabis use, the concept of medical cannabis, and synthetic cannabinoids as new psychoactive substances (nps). |
2019-01-14 |
2023-08-13 |
Not clear |
| Cinzia Citti, Federica Palazzoli, Manuela Licata, Antonietta Vilella, Giuseppina Leo, Michele Zoli, Maria Angela Vandelli, Flavio Forni, Barbara Pacchetti, Giuseppe Cannazz. Untargeted rat brain metabolomics after oral administration of a single high dose of cannabidiol. Journal of pharmaceutical and biomedical analysis. vol 161. 2019-01-10. PMID:30138822. |
cannabidiol (cbd), for long time considered as a minor cannabinoid of cannabis sativa, has recently gained much attention due to its antioxidant, anti-inflammatory, analgesic and anticonvulsant properties. |
2019-01-10 |
2023-08-13 |
rat |
| Anissa Bara, Antonia Manduca, Axel Bernabeu, Milene Borsoi, Michela Serviado, Olivier Lassalle, Michelle Murphy, Jim Wager-Miller, Ken Mackie, Anne-Laure Pelissier-Alicot, Viviana Trezza, Olivier J Manzon. Sex-dependent effects of in utero cannabinoid exposure on cortical function. eLife. vol 7. 2019-01-07. PMID:30201092. |
despite increasing reports of cannabis consumption during pregnancy, the protracted consequences of prenatal cannabinoid exposure (pce) remain incompletely understood. |
2019-01-07 |
2023-08-13 |
rat |
| Carmen De Caro, Antonio Leo, Rita Citraro, Caterina De Sarro, Roberto Russo, Antonio Calignano, Emilio Russ. The potential role of cannabinoids in epilepsy treatment. Expert review of neurotherapeutics. vol 17. issue 11. 2019-01-03. PMID:28845714. |
therefore, new drugs are needed and cannabinoids, above all cannabidiol, have recently gathered attention. |
2019-01-03 |
2023-08-13 |
human |
| Carmen De Caro, Antonio Leo, Rita Citraro, Caterina De Sarro, Roberto Russo, Antonio Calignano, Emilio Russ. The potential role of cannabinoids in epilepsy treatment. Expert review of neurotherapeutics. vol 17. issue 11. 2019-01-03. PMID:28845714. |
expert commentary: despite the fact that cannabis has been used for many purposes over 4 millennia, the development of drugs based on cannabinoids has been very slow. |
2019-01-03 |
2023-08-13 |
human |
| Cristina Casajuana Köguel, Hugo López-Pelayo, Mª Mercedes Balcells-Olivero, Joan Colom, Antoni Gua. Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones. vol 30. issue 2. 2019-01-02. PMID:28492950. |
objective this systematic review aims to summarize current evidence on which naturally present cannabinoids contribute to cannabis psychoactivity, considering their reported concentrations and pharmacodynamics in humans. |
2019-01-02 |
2023-08-13 |
human |
| Cristina Casajuana Köguel, Hugo López-Pelayo, Mª Mercedes Balcells-Olivero, Joan Colom, Antoni Gua. Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones. vol 30. issue 2. 2019-01-02. PMID:28492950. |
due to lower psychoactive potency and smaller proportions in plant material, other psychoactive cannabinoids have a weak influence on cannabis final effects. |
2019-01-02 |
2023-08-13 |
human |
| Valerio Chiurchiù, Mario van der Stelt, Diego Centonze, Mauro Maccarron. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Progress in neurobiology. vol 160. 2019-01-02. PMID:29097192. |
both preclinical and clinical data suggest that cannabinoids, derived from the cannabis sativa plant, may be used to control symptoms such as spasticity and chronic pain, whereas only preclinical data indicate that these compounds and their endogenous counterparts, i.e. |
2019-01-02 |
2023-08-13 |
Not clear |
| Roger Hudson, Walter Rushlow, Steven R Laviolett. Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29063964. |
in contrast, delta-9-tetrahydrocannabinol (thc), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (cb1rs). |
2018-12-31 |
2023-08-13 |
Not clear |
| Vincenzo Micale, Filippo Drag. Endocannabinoid system, stress and HPA axis. European journal of pharmacology. vol 834. 2018-12-18. PMID:30036537. |
the endocannabinoid system (ecs), which is composed of the cannabinoid receptors types 1 and 2 (cb1 and cb2) for marijuana's psychoactive ingredient ∆ |
2018-12-18 |
2023-08-13 |
Not clear |
| Ahna Brutlag, Holly Hommerdin. Toxicology of Marijuana, Synthetic Cannabinoids, and Cannabidiol in Dogs and Cats. The Veterinary clinics of North America. Small animal practice. vol 48. issue 6. 2018-12-17. PMID:30342565. |
toxicology of marijuana, synthetic cannabinoids, and cannabidiol in dogs and cats. |
2018-12-17 |
2023-08-13 |
Not clear |
| Ahna Brutlag, Holly Hommerdin. Toxicology of Marijuana, Synthetic Cannabinoids, and Cannabidiol in Dogs and Cats. The Veterinary clinics of North America. Small animal practice. vol 48. issue 6. 2018-12-17. PMID:30342565. |
this article provides a brief history of cannabis along with a review of the endocannabinoid system, common cannabis products, expected clinical signs, and medical treatment approaches associated with cannabis exposure in pets. |
2018-12-17 |
2023-08-13 |
Not clear |
| Roberta Z Horth, Barbara Crouch, B Zane Horowitz, Amelia Prebish, Matthew Slawson, Jennifer McNair, Chris Elsholz, Stephen Gilley, Jenny Robertson, Ilene Risk, Mary Hill, Linnea Fletcher, Wei Hou, Dallin Peterson, Karlee Adams, Dagmar Vitek, Allyn Nakashima, Angela Dun. Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol - Utah, 2017-2018. MMWR. Morbidity and mortality weekly report. vol 67. issue 20. 2018-12-12. PMID:29795081. |
notes from the field: acute poisonings from a synthetic cannabinoid sold as cannabidiol - utah, 2017-2018. |
2018-12-12 |
2023-08-13 |
Not clear |
| Marilyn A Huestis, Michael L Smit. Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. Trends in molecular medicine. vol 24. issue 2. 2018-12-11. PMID:29398403. |
understanding cannabis and synthetic cannabinoid intake history is vital for treating drug dependence, investigating cannabinoid effects, and providing information to healthcare personnel, medical examiners, and public health officials; this is particularly relevant today with cannabis medicalization and legalization. |
2018-12-11 |
2023-08-13 |
Not clear |
| Marilyn A Huestis, Michael L Smit. Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. Trends in molecular medicine. vol 24. issue 2. 2018-12-11. PMID:29398403. |
future challenges include developing behavioral markers of cannabis impairment, bringing to market breathalyzers for cannabinoid detection, and identifying markers of recent cannabis intake in diverse biological matrices. |
2018-12-11 |
2023-08-13 |
Not clear |
| Marilyn A Huestis, Michael L Smit. Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. Trends in molecular medicine. vol 24. issue 2. 2018-12-11. PMID:29398403. |
we posit that biological monitoring of cannabinoids and metabolites will improve the characterization of cannabis and synthetic cannabinoid intake history. |
2018-12-11 |
2023-08-13 |
Not clear |
| Hanife Yilmaz Cengel, Muge Bozkurt, Cuneyt Evren, Gokhan Umut, Cahit Keskinkilic, Ruken Agachanl. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry research. vol 262. 2018-12-11. PMID:29407568. |
evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. |
2018-12-11 |
2023-08-13 |
human |
| Hanife Yilmaz Cengel, Muge Bozkurt, Cuneyt Evren, Gokhan Umut, Cahit Keskinkilic, Ruken Agachanl. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry research. vol 262. 2018-12-11. PMID:29407568. |
the present study aims to investigate the attention, memory, visuospatial and executive functions in individuals with synthetic cannabinoid use disorder and compare the results with findings obtained from individuals with cannabis use disorder and healthy volunteers with no substance use. |
2018-12-11 |
2023-08-13 |
human |
| Hanife Yilmaz Cengel, Muge Bozkurt, Cuneyt Evren, Gokhan Umut, Cahit Keskinkilic, Ruken Agachanl. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry research. vol 262. 2018-12-11. PMID:29407568. |
fifty-two patients with synthetic cannabinoid use disorder, 45 patients with cannabis use disorder and 48 healthy control group males were included in the study. |
2018-12-11 |
2023-08-13 |
human |
| Hanife Yilmaz Cengel, Muge Bozkurt, Cuneyt Evren, Gokhan Umut, Cahit Keskinkilic, Ruken Agachanl. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry research. vol 262. 2018-12-11. PMID:29407568. |
impairments in attention, memory, executive and visuospatial functions were identified in individuals with synthetic cannabinoid use disorder and these impairments were found to be significantly greater than in individuals with cannabis use disorder and healthy controls. |
2018-12-11 |
2023-08-13 |
human |